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Abstract
Background: The amyloid precursor protein (APP) is genetically associated with Alzheimer's
disease (AD). Elucidating the function of APP should help understand AD pathogenesis and provide
insights into therapeutic designs against this devastating neurodegenerative disease.
Results:  We demonstrate that APP expression in primary neurons induces β-catenin
phosphorylation at Ser33, Ser37, and Thr41 (S33/37/T41) residues, which is a prerequisite for β-
catenin ubiquitinylation and proteasomal degradation. APP-induced phosphorylation of β-catenin
resulted in the reduction of total β-catenin levels, suggesting that APP expression promotes β-
catenin degradation. In contrast, treatment of neurons with APP siRNAs increased total β-catenin
levels and decreased β-catenin phosphorylation at residues S33/37/T41. Further, β-catenin was
dramatically increased in hippocampal CA1 pyramidal cells from APP knockout animals. Acute
expression of wild type APP or of familial AD APP mutants in primary neurons downregulated β-
catenin in membrane and cytosolic fractions, and did not appear to affect nuclear β-catenin or β-
catenin-dependent transcription. Conversely, in APP knockout CA1 pyramidal cells, accumulation
of β-catenin was associated with the upregulation of cyclin D1, a downstream target of β-catenin
signaling. Together, these data establish that APP downregulates β-catenin and suggest a role for
APP in sustaining neuronal function by preventing cell cycle reactivation and maintaining synaptic
integrity.
Conclusion: We have provided strong evidence that APP modulates β-catenin degradation in vitro
and in vivo. Future studies may investigate whether APP processing is necessary for β-catenin
downregulation, and determine if excessive APP expression contributes to AD pathogenesis
through abnormal β-catenin downregulation.
Background
β-Catenin plays a central role in Wnt signalling in the
canonical pathway [1]. In the absence of Wnt signalling,
cytoplasmic β-catenin exists in a complex together with
axin, adenomatous polyposis coli (APC), and glycogen
synthase kinase (GSK)-3β. GSK-3β constitutively phos-
phorylates β-catenin at Ser33, Ser37, and Thr41 (S33/37/
T41) residues, triggering ubiquitinylation by a Cullin-1-
containing E3 ligase (also known as the SCF complex)
before proteasomal degradation [2-6]. Signalling by Wnt
through Frizzled and LRP cell surface receptors inhibits
GSK-3β and stabilizes β-catenin. When stabilized, β-cat-
enin translocates to the nucleus and functions as a tran-
Published: 10 December 2007
Journal of Neuroinflammation 2007, 4:29 doi:10.1186/1742-2094-4-29
Received: 2 October 2007
Accepted: 10 December 2007
This article is available from: http://www.jneuroinflammation.com/content/4/1/29
© 2007 Chen and Bodles; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Neuroinflammation 2007, 4:29 http://www.jneuroinflammation.com/content/4/1/29
Page 2 of 10
(page number not for citation purposes)
scription cofactor of the T cell factor (TCF), activating
responsive genes such as cyclin D1 and c-myc.
Several lines of evidence suggest that APP influences β-cat-
enin regulation. APP binds to APP-BP1 which activates
the small ubiquitin-like protein Nedd8 [7,8]. Activated
Nedd8 modifies Cullins which then becomes more stable.
When Cullin-1 in SCF is transiently stabilized, it increases
β-catenin ubiquitinylation and degradation [9]. In addi-
tion, APP plays an important role in cell-cell adhesion
[10], a function that may involve β-catenin. Membrane-
associated  β-catenin anchors cadherins to the actin
cytoskeleton [11]. Interactions with cadherins may under-
lie an important role for β-catenin in synaptic integrity of
neurons [12]. Synaptic dysfunction is one of the earliest
events in AD pathogenesis [13], and APP appears to con-
tribute to synapse formation or stabilization [14-16].
Both APP and Presenilins are genetically associated with
AD. In addition to its role in APP processing, Presenilin-1
(PS1) also interacts with the cadherin/catenin adhesion
complex [17] and affects β-catenin delivery to the mem-
brane adhesion complex [18]. There is some controversy
surrounding the influence of PS1 and its FAD mutants on
β-catenin [19-26]. Similarly, different levels of β-catenin
have been reported in AD [27-29]. This is likely attributa-
ble to the complexity of these systems made possible by
multimodal interactions between APP, PS1, β-catenin,
and E-cadherin; a complexity that justifies more detailed
analyses of these systems. The purpose of this report is to
determine whether APP mediates β-catenin degradation
in vitro and in vivo. We provide critical evidence that APP
downregulates β-catenin in neurons.
Methods
Primary neurons
Pregnant Sprague-Dawley rats (E18, Charles River, Wilm-
ington, MA) were euthanized after being rendered uncon-
scious with CO2 according to the protocol approved by
the Institutional Animal Care and Use Committee. The
cortices from embryonic brains were gently triturated with
a fine-tipped transfer pipette right after dissection. Single
cells were counted and immediately plated in Neurobasal
medium containing B27 supplements (Invitrogen,
Calsbad, CA), 0.5 mM glutamine, 1% FBS, 1% equine
serum, and 1× penicillin/streptomycin (Sigma, St. Louis,
MO) at a density of 4 × 106 per 60-mm dish or 4 × 105 per
well of 24-well plate on poly-D-lysine-coated dishes. The
medium was replaced with fresh medium at 2 h after plat-
ing. Half of the medium was replaced with fresh medium
every three days. The adult rat brain and other organs were
dissected and frozen on dry ice before lysis and immuno-
blot analyses. Primary neurons were used at 7 DIV unless
noted otherwise.
HSV expression vectors and viral titers
Constructs of full length APP (APP695), mycAPP-BP1, and
LacZ (expresses β-galactosidase) in the pHSVprPUC vector
[7,30] were packaged into HSV-1 virus using the 2-2 cell
line as described by Lim et al. [31]. Each viral stock infec-
tious unit (IU) was determined by counting ten randomly
selected fields of infected primary neurons immuno-
stained for APP and myc tag, or cytochemically stained for
β-galactosidase using X-gal substrate (Roche).
Short hairpin RNA (shRNA)
RNA interference was achieved via shRNAs expressed
from the pHSVGET vector for neuronal expression [32].
Each shRNA duplex was designed with a TCA AGA G loop.
The APP shRNA was targeted to the following sequence:
5'-GCA GAA GAT GTG GGT TCA AAC-3' (APP1996). The
control shRNA included the missense sequence 5'-GCT
TCA TAA GGC GCA TAG CTA-3'. In some experiments,
the vector pHSVGET was used as a control. All constructs
were sequenced before HSV viral packaging. Viruses were
packaged as described [31]. The IU of each shRNA virus
was determined by the number of EGFP-expressing cells
after infecting primary neurons for 15 hours. EGFP-posi-
tive cells were visualized by fluorescence microscopy after
fixation in 4% paraformaldehyde for 15 min at room tem-
perature.
Neuron infection, western blots, and antibodies
For all western blot analyses, primary neurons in 60-mm
dishes were infected at 7 DIV with 1 or 2 IU per cell (for
protein expression), or at 0.5 or 1 IU per cell (for shRNA
knockdown analyses). At 14–15 h after infection, cells
were washed with cold phosphate-buffered saline (PBS)
and sonicated in lysis buffer (150 mM NaCl, 50 mM
sodium fluoride, 50 mM Tris-HCL, 10 mM β-glycerol
phosphate, 5 mM EDTA, 5 mM iodoacetamide, 1 mM
phenylmethylsulfonylfluoride, 1 mM sodium orthovana-
date, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS,
pH 8.0). Protein concentrations were determined by the
bicinchronic acid (BCA) method; equal amount of pro-
tein was boiled in SDS sample buffer and resolved on
SDS-PAGE gels. The following antibodies were used: rab-
bit anti-β-catenin and mouse anti-γ-tubulin (both from
Sigma); anti-phosphorylated β-catenin antibodies, S33/
37/T41 and S45 (both from Cell Signaling); rabbit anti-
APP antibody (369, a gift from Dr. Sam Gandy). Chemi-
luminescence reactions were carried out using Chemi-
Glow (Alpha Innotech) and the blot digital images were
collected by the AlphaEase FC™ Imaging System and the
FluorChem™ IS-8800 software (Alpha Innotech). Multi-
ple exposures of each blot were routinely taken, and the
exposure that had specific protein bands within the linear
range in optical density was used for densitometry.Journal of Neuroinflammation 2007, 4:29 http://www.jneuroinflammation.com/content/4/1/29
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Quantitative western blot analyses were based on three or
more independent experiments after densitometry tracing
of specific protein bands using the Scion Image software
(version 4.0.3.2, Scion Corporation). The optical densities
of the protein bands in equal area of space were deter-
mined after subtracting the background per individual
lane. In order to analyze the results across different exper-
iments, the optical density levels were then normalized to
γ-tubulin expressions in the respective western blot. The
normalized density units were then analyzed by one-tail
or two-tail t-Tests (more stringent) for two samples
assuming unequal variance using the EXCEL data analysis
tool (Microsoft Corporation). A p value of 0.05 or less was
considered to be statistically significant.
Cell membrane, cytosolic and nuclear fractions
The post-nuclear membrane fraction was isolated as
described [33]. Briefly, after transfection of HEK293 cells
for 40 hours, or after infection of primary neuronal cul-
tures for 15 hours, the medium was withdrawn, and cells
were harvested in ice-cold PBS, washed once, and homog-
enized by shearing through a 22-ga needle in buffer HS
(250 mM sucrose, 150 mM NaCl, 10 mM Tris-HCl, and 5
mM EDTA, pH 7.4) supplemented with a mixture of pro-
tease inhibitors (Sigma). All subsequent steps were carried
out on ice unless indicated otherwise. The crude nuclear
fraction was saved after the samples were centrifuged at
1500 × g for 10 min and resuspended in buffer HD (10
mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% SDS, and 5 mM
EDTA) with protease inhibitors. Membrane fractions were
collected from the postnuclear supernatants by centrifuga-
tion for 20 min at 14,000 × g and resuspended in buffer
HD with protease inhibitors. Proteins in the supernatant
(cytosolic fraction) were precipitated with 20% trichloro-
acetic acid. The precipitated proteins were washed with
95% ethanol. Protein pellets were resuspended in 1% Tri-
ton X-100 containing protease inhibitor mix (1:250).
Equal amount of proteins from membrane, cytosolic or
nuclear fractions were resolved by SDS-PAGE, transferred
to nitrocellulose membrane, and analyzed for β-catenin
by western blot analyses.
Dual luciferase assays
HEK293 cells were transfected with pGL3-OT or pGL-OF
(improved versions of pTOPflash and pFOPflash, respec-
tively) [34] and APP or a mutant APP construct. Renella
luciferase reporter (CMV-PRL, Promega) was included in
each sample to normalize transfection efficiency. The pos-
itive control was prepared from cells transfected with β-
catenin [35]. Cells were harvested at 40 h after transfec-
tion and dual luciferase assays were performed as
described in the manufacturer's protocol (Promega). Luci-
ferase activity was measured by a dual-injector microplate
luminometer (Turner Biosystems) using Veritas program.
Immunofluorescence microscopy
Primary neurons were fixed with 4% paraformaldehyde
for 40 m at room temperature. Cells were then washed
with PBS, blocked with 3% normal goat serum, and
stained with rabbit anti-β-catenin (Sigma) for 2 h at room
temperature. Cells were then washed and incubated with
Alexa Fluor 488-conjugated goat anti-rabbit for 1 h
(Molecular Probe). Counterstaining with DAPI was per-
formed in some cells by incubating for 2 m with DAPI (20
µg/ml). After 4× washes in PBS, cells were mounted in
90% glycerol. Negative controls were without primary
antibodies. The specificity of the anti-β-catenin antibody
was also demonstrated in western blots. Confocal images
were taken under a 63× objective with a Nikon D-Eclipse
C1 confocal microscope through z-series at the same set-
tings. Individual z-sections and composite images were
further grouped in Photoshop (version 6.0, Adobe).
APP knockout animals and immunofluorescence labelling
APP knockout animals were raised and genotyped as
described before (n = 4; 3 were 8 months old and 1 was
18 months old) and WT controls (n = 4; 3 were 8.5
months old and one was 7 months old) [36]. Brain sec-
tions (6 µm thick) were pre-incubated with 2N HCl for 30
m, washed 6×, blocked with 3% normal goat serum, and
incubated overnight in primary antibodies. The sections
were then washed 3×, and incubated in secondary anti-
bodies for 1 h before incubation in DAPI solution for 2 m.
Sections were washed and mounted in 90% glycerol.
Images were obtained at the same settings with a Nikon
Eclipse 600 fluorescence microscope and CoolSnap dig-
ital camera using MetaVue software (version 6.2r2, Molec-
ular Devices Corporation). The pixel density of the CA1
pyramidal cells in the cell body layer were sampled using
the MetaVue software. The mean value of pixel density
was calculated and compared by two-tailed t-Test assum-
ing unequal variance (Excel, Microsoft).
Results
APP downregulates β-catenin in primary neurons
To determine the effect of APP on β-catenin, full length
human APP695 was expressed in primary neurons using
HSV-1 vector-mediated gene transfer. An increase in APP
levels resulted in a significant decrease in total β-catenin
(Fig. 1). Quantification indicated that a tripling of APP (at
2 IU of virus) was associated with a reduction of β-catenin
to approximately half of that in the control (LacZ).
APP facilitates β-catenin degradation by increasing β-
catenin phosphorylation at S33/37/T41
Levels of β-catenin are tightly regulated by phosphoryla-
tion, ubiquitinylation, and proteasomal degradation.
Amino acids S33/37/T41 of β-catenin are co-ordinately
phosphorylated by GSK-3β before ubiquitinylation and
degradation. Casein kinase 1 additionally phosphorylatesJournal of Neuroinflammation 2007, 4:29 http://www.jneuroinflammation.com/content/4/1/29
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β-catenin at Ser45 (S45) [37]. To determine whether APP
affected these phosphorylation events, we used β-catenin
phosphorylation-specific antibodies to compare neurons
infected with APP or the control virus (LacZ). Statistical
analyses revealed that APP over-expression in primary
neurons significantly increased S33/37/T41 phosphoryla-
tion (p < 0.02) without significantly altering S45 phos-
phorylation. Representative blots along with quantitative
analyses are presented in Figure 2.
Downregulating endogenous APP significantly inhibits β-
catenin phosphorylation at S33/37/T41 but not at S45
To exclude the possibility that enhanced β-catenin degra-
dation was due to a gain-of-function artifact when APP is
over-expressed, we used siRNAs to suppress the expres-
sion of endogenous APP. An HSV-1 shRNA vector was
used to express siRNAs (APP1996) targeting rat APP in
primary neurons; no human APP was expressed in these
experiments. Protein levels were quantified by densitom-
etry, with tracing and normalization to the levels of γ-
tubulin on each blot. Statistical analyses by t-Test revealed
that suppressing the endogenous APP by this means
resulted in a significant increase in total β-catenin com-
pared to the control (missense shRNA) (Fig. 3). APP
downregulation also significantly reduced β-catenin
phosphorylation at S33/37/T41, but did not significantly
affect phosphorylation at S45. These results extend the
inverse relationship between APP and β-catenin levels.
APP-expression decreases β-catenin in membrane and 
cytosolic fractions without affecting nuclear β-catenin
The function of β-catenin differs depending on its cellular
location. We sought to determine if APP expression differ-
entially affects β-catenin levels in crude preparations of
membrane, cytosolic or nuclear fractions. Three forms of
APP were tested: wild-type, Swedish mutation (Swe), and
London mutation (V642I). In primary neurons, wild-type
APP and each of the FAD mutants dramatically reduced
total β-catenin compared to the control (LacZ) in both
membrane and cytosolic fractions (Fig. 4A). APP
decreased β-catenin levels to 48% of control in the mem-
brane and to 29% of control in the cytosol (average of two
independent experiments in primary neurons). These
results were corroborated by data from HEK293 cells
transfected with the same APP cDNAs expressed from
pcDNA3 constructs (data not shown).
In contrast to membrane and cytosolic β-catenin, nuclear
β-catenin did not appear to change upon expression of
wild-type or FAD APP (Fig. 4A). To obtain further support
for the fractionation experiments, we then tested the
nuclear function of β-catenin using luciferase reporter
assays. HEK293 cells were transfected with wild-type or
FAD APP, along with the TCF luciferase reporter plasmid
(pGL3-OT). None of the APP constructs consistently
decreased pGL3-OT luciferase reporter activity. Controls
included cotransfection of a mutant TCF luciferase
reporter (pGL3-OF) with APP, and cotransfection of
APP expression induced degradation of β-catenin Figure 1
APP expression induced degradation of β-catenin. A. 
Overexpression of APP reduces β-catenin levels. Human 
APP695 or the control LacZ was expressed in primary neu-
rons via HSV vectors at 1 or 2 IU per cell during 14 h of 
infection. The control HSV vector carries the β-galactosidase 
gene (LacZ). B. Quantitative densitometric analyses of west-
ern blots from 4 independent experiments. An average 44% 
reduction in normalized mean optical density (representing 
protein levels) was observed for 2 IU/cell of APP compared 
to the corresponding LacZ control (p < 0.05, t-Test). Shorter 
exposures were used for densitometry analyses; longer 
exposures also showed the expression of endogenous APP, 
but densitometric analyses were not possible due to the 
solidified chemiluminescence reaction products.Journal of Neuroinflammation 2007, 4:29 http://www.jneuroinflammation.com/content/4/1/29
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pGL3-OT with pcDNA3 (data not shown). A positive con-
trol was prepared from cells transfected with a β-catenin
expression construct and the pGL3-OT plasmid. Together,
these data suggest that APP may not affect β-catenin tran-
scriptional activity.
To complement the above experiments, confocal micros-
copy was used to assess β-catenin levels and cellular loca-
tions in primary neurons. Primary neurons expressing
APP or LacZ (control) were fixed and labelled with the
rabbit anti-β-catenin antibody and the Alexa fluor 488
goat anti-rabbit antibody. Representative z-sections of the
same cells are presented in Fig. 4B. The z-sections show
abundant β-catenin present near or at the plasma mem-
brane. More β-catenin seemed to localize in the basal-lat-
eral than apical regions, and APP expression did not seem
to affect β-catenin localization compared to the LacZ con-
trol. The z-series (Fig. 4B) and the composite images (Fig.
4C) also revealed that β-catenin fluorescence intensity
decreased dramatically in APP-expressing neurons com-
pared to the LacZ control, further supporting the data
obtained by fractionation assays.
APP facilitates β-catenin degradation by increasing β-catenin  phosphorylation at S33/37/T41 residues Figure 2
APP facilitates β-catenin degradation by increasing β-
catenin phosphorylation at S33/37/T41 residues. A. 
Primary neurons infected with APP contained less steady-
state β-catenin and higher levels of phosphorylated S33/37/
T41 than did neurons infected with control LacZ (2 IU virus 
per cell). Levels of phosphorylated S45 did not appear to 
change. B. Quantitative analyses of western blots from 3 
independent experiments. APP significantly increased β-cat-
enin phosphorylation at S33/37/T41 residues (p = 0.02, t-
Test), but not at S45 residue (p = 0.19, t-Test).
Suppression of endogenous APP results in increased total β- catenin and decreased S33/37/T41-phosphorylated β-catenin Figure 3
Suppression of endogenous APP results in increased 
total β-catenin and decreased S33/37/T41-phosphor-
ylated β-catenin. Primary neurons were infected with APP-
shRNA (APP1996) or missense shRNA viruses (0.5 IU/cell) 
for 14 h before harvest and protein analyses. The mean opti-
cal densities of 3 independent experiments for each protein 
analyzed are presented in the Y-axis in the bar graphs. The 
statistical significance of difference is also presented in each 
bar graph (p values from t-Test) for each protein analyzed 
(labelled on the Y-axis). Representative blots are shown on 
the right. Loading controls were γ-tubulin reprobed from the 
same blots.Journal of Neuroinflammation 2007, 4:29 http://www.jneuroinflammation.com/content/4/1/29
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APP expression downregulates β-catenin levels in membrane and cytosolic fractions but not in the nuclear fraction Figure 4
APP expression downregulates β-catenin levels in membrane and cytosolic fractions but not in the nuclear 
fraction. A. β-Catenin levels from membrane and cytosolic fractions isolated from primary neurons. Wild type or FAD APPs 
were overexpressed in primary neurons via HSV-mediated gene transfer using LacZ as the control. 10 µg protein per sample 
was analyzed in each fraction. B. Selected z-series of single cells. Scale bar, 2 µm. C. Composite images from z-series. Scale bar, 
5 µm. In both B and C, primary neurons were infected with APP or the control LacZ viruses at 2 IU/cell for 14 h. Cells were 
then fixed and stained with rabbit anti-β-catenin and Alexa fluor 488 goat anti-rabbit. Images were collected at the same set-
tings for fluorescence intensity comparison.Journal of Neuroinflammation 2007, 4:29 http://www.jneuroinflammation.com/content/4/1/29
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β-Catenin is significantly increased in CA1 pyramidal cells 
from APP knockout animals
The results presented above show that APP mediates β-cat-
enin degradation in primary neurons. We next sought to
determine if β-catenin levels are altered in CA1 pyramidal
cells from APP knockout animals. Fig. 5 shows that β-cat-
enin is significantly elevated in APP knockout pyramidal
cells compared to wild-type controls (Fig. 5A &5B). These
increases in β-catenin were associated with significant
increases in cyclin D1 expression (Fig. 5A &5C). These
data suggest that chronically increased β-catenin levels in
these neurons might result in cell cycle reactivation. These
data further support our findings in primary neurons sug-
gesting that APP mediates β-catenin homeostasis.
Discussion
In this report, we provide strong evidence that APP medi-
ates β-catenin downregulation. We demonstrate that APP
downregulates  β-catenin levels in primary neurons by
facilitating specific phosphorylation of S33/37/T41 resi-
β-Catenin and cyclin D1 are significantly elevated in hippocampal CA1 pyramidal cells in APP knockout mice compared to  those in WT controls Figure 5
β-Catenin and cyclin D1 are significantly elevated in hippocampal CA1 pyramidal cells in APP knockout mice 
compared to those in WT controls. Brain sections from APP knockout and WT mice (n = 4 each) were co-labelled with 
rabbit anti-β-catenin and mouse anti-cyclin D1 together with Alexa Fluor 594 and Alexa Fluor 488 secondary antibodies. The 
sections were also counter-stained with DAPI to visualize the cell body layer. Images were captured at the same settings with 
a Nikon Eclipse 600 microscope. Representative images from an APP knockout and a WT animal are presented in A. The pixel 
density of specific staining was randomly sampled in the CA1 cell body layer and the mean values from each group of animals 
are shown in the bar graphs: B. β-catenin, two-tail t-Test, APP knockout vs AT, p = 0.001; C. cyclin D1, two-tail t-Test, APP 
knockout vs WT, p = 0.02.Journal of Neuroinflammation 2007, 4:29 http://www.jneuroinflammation.com/content/4/1/29
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dues in β-catenin. APP expression is inversely correlated
with the levels of total β-catenin. Corroborating data were
obtained using APP siRNAs: suppression of APP by siR-
NAs increased steady-state β-catenin levels and reduced
the levels of S33/37/T41 phosphorylation in neurons. We
further show that β-catenin accumulates in hippocampal
pyramidal cells in APP knockout animals. Together, these
data establish that APP is physiologically important in
maintaining β-catenin homeostasis, which is likely critical
for neuronal survival and function by preventing aberrant
cell cycle reaction.
We show that familial AD mutants of APP induce similar
β-catenin degradation, suggesting that familial AD
mutants retain similar functions. Our method might not
be sensitive enough to detect the degree of differences in
β-catenin downregulation by these APP mutants upon
acute expression in cell cultures. Long-term effects of APP
mutants on β-catenin expression could be analyzed in
transgenic animals. In primary neurons, APP-induced β-
catenin downregulation did not appear to affect nuclear β-
catenin or its transcriptional activity. However, β-catenin
accumulation in CA1 pyramidal neurons from APP
knockout animals does appear to affect transcriptional
activity, judging from the increases found in cyclin D1
protein levels in these same neurons. These observations
illustrate the limitations of luciferase reporter assays in
primary neurons; they also suggest that basal levels of β-
catenin are necessary for neuronal function, but that these
do not necessarily affect β-catenin-mediated transcrip-
tion.
Several questions remain to be answered, such as whether
APP processing products, such as secreted APP, or Aβ,
mediate the effect of APP on β-catenin degradation. The
effect of APP on β-catenin phosphorylation could also
reflect the interaction between APP and APP-BP1. APP-
BP1 activates neddylation and increases ubiquitinylation
by the Cullin-based E3 ligase. Ubiquitinylation of β-cat-
enin may be facilitated by the interaction between APP
and APP-BP1, which is not unidirectional as indicated by
the studies in Drosophila [38]. We have recently shown
that one function of APP-BP1 is to downregulate Aβ1–42 in
primary neurons [32]. Aβ1–42 also appears to downregu-
late β-catenin (YC unpublished observations). However,
it remains to be determined whether APP and Aβ1–42 mod-
ulate β-catenin degradation through the same pathways.
The roles of APP and PS1 on β-catenin phosphorylation
may be independent of each other. We show that APP
facilitates β-catenin phosphorylation at S33/37/T41 resi-
dues. Others have shown that PS1 expression can enhance
phosphorylation of β-catenin at S45, which may prime
the phosphorylation of S33/37/T41 [39] and facilitate
membrane  β-catenin delivery and degradation [17,18].
The ultimate effect of PS1 on β-catenin degradation
remains controversial. Some studies have shown destabi-
lization of β-catenin by wild-type PS1 but inactivity of the
FAD-mutant forms of PS1 [20,22]; others have shown the
opposite [27]. Serban et al. [24] argued that the ultimate
outcome rests on the inherent levels of E-cadherin. Our
new findings suggest that PS1 and APP may impinge on
different components in the β-catenin degradation path-
way, but the underlying mechanism needs to be further
investigated.
Our new findings not only support a critical role for APP
in maintaining neuronal differentiation but also support
a role for APP in synaptic dynamics due to the multifac-
eted functions of β-catenin [40,41]. Cell cycle events are
widely documented in post-mortem AD brain tissues
[42]. In several AD cases which we have examined, almost
all hippocampal neurons show signs of cell cycle entry as
indicated by the cytoplasmic translocation of Nedd8 [7].
This cell cycle deregulation and synaptic dysfunction may
well be related [43]. Our new findings suggest a dysfunc-
tion of APP in maintaining neuronal differentiation in AD
neurons. However, levels of APP itself must be regulated,
as high levels of APP could induce neuronal death [7,44];
our new evidence suggest that low levels of APP may be
equally detrimental to neurons due to β-catenin accumu-
lation. We observed a large amount of β-catenin in the
plasma membranes of primary neurons (Fig. 4), in accord
with findings reported in Drosophila [18]. Membrane β-
catenin is known to play a role in dendritic remodeling in
mature neurons [45]. Synaptic dynamics may involve
changes in the interaction of β-catenin with cytosolic or
membrane proteins such as with E-cadherin. These con-
siderations, taken together, implicate APP as a critical fac-
tor in neuronal function that warrants further
investigation.
Conclusion
In summary, this report documents a function of APP in
β-catenin downregulation in vivo and in vitro. These find-
ings open new avenues for research involving the role of
APP processing in β-catenin downregulation. Future stud-
ies may also determine whether excessive APP expression
contributes to AD pathogenesis involving abnormal β-cat-
enin phosphorylation and degradation in transgenic ani-
mals.
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